Avalon GloboCare Corp.

Equities

ALBT

US05344R2031

Healthcare Facilities & Services

Market Closed - Nasdaq Other stock markets 02:00:00 23/05/2024 am IST			5-day change	1st Jan Change
0.295 ^USD	+1.69%		+11.83%	-38.92%

22/04	Avalon GloboCare Corp. Announces Launch of U.S. Sales of KetoAir Breathalyzer at the Hack Your Health by KetoCon 2024 Conference	CI
17/04	North American Morning Briefing : Stock Futures -2-	DJ

Avalon Globocare Corp. Appoints Yen-Michael S. Hsu to its Scientific and Clinical Advisory Board

June 26, 2019 at 06:00 pm IST

Avalon GloboCare Corp. announced that the company has appointed Yen-Michael S. Hsu to its Scientific and Clinical Advisory Board. Dr. Yen-Michael Sheng Hsu is currently the Director of Laboratory for Advanced Cellular Therapy at Weill Cornell Medicine.

Latest news about Avalon GloboCare Corp.

Avalon GloboCare Corp. Announces Launch of U.S. Sales of KetoAir Breathalyzer at the Hack Your Health by KetoCon 2024 Conference	22/04	CI
North American Morning Briefing : Stock Futures -2-	17/04	DJ
Avalon GloboCare Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	16/04	CI
North American Morning Briefing : Traders Await -2-	10/04	DJ
North American Morning Briefing : Powell Awaited -2-	03/04	DJ
Avalon GloboCare Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	15/11	CI
Avalon GloboCare Corp. announced that it has received $0.665 million in funding from Mast Hill Management, LLC, FirstFire Capital Management LLC	11/23/11	CI
Avalon GloboCare Corp. announced that it expects to receive $0.665 million in funding from Mast Hill Management, LLC, FirstFire Capital Management LLC	09/23/09	CI
Top Midday Gainers	05/23/05	MT
Avalon Says Laboratory Services Launches New Tuberculosis Test; Shares Rise	30/23/30	MT
North American Morning Briefing : Treasury Yields Keep Pushing Higher	17/23/17	DJ
Avalon GloboCare Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	15/23/15	CI
Avalon GloboCare-Owned Laboratory Services MSO Acquires DE Laboratory	24/23/24	MT
Avalon Globocare Says Laboratory Services MSO Has Testing-Service Deal With GeneX Laboratory	19/23/19	MT
Avalon Globocare's Laboratory Services MSO Signs Exclusive In-Network Lab Services Agreement Providing Significant Expansion Opportunity into 21 States	19/23/19	CI
Avalon GloboCare Corp. announced that it has received $0.475 million in funding from FirstFire Capital Management LLC	07/23/07	CI
Avalon GloboCare Corp. announced that it expects to receive $0.5 million in funding from FirstFire Capital Management LLC	06/23/06	CI
Avalon GloboCare Corp. announced that it has received $1.425 million in funding from Mast Hill Management, LLC	23/23/23	CI
Avalon GloboCare Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023	23/23/23	CI
North American Morning Briefing : Powell on Tap -2-	19/23/19	DJ
North American Morning Briefing : Hopes of Easing -2-	12/23/12	DJ
Avalon GloboCare Corp. Reports Earnings Results for the Full Year Ended December 31, 2022	31/23/31	CI
Avalon GloboCare Corp. Auditor Raises 'Going Concern' Doubt	30/23/30	CI
Avalon GloboCare Corp. announced that it expects to receive $11 million in funding	13/23/13	CI
Avalon GloboCare Corp. completed the acquisition of a 40% stake in Laboratory Services MSO, LLC from Zoe Family Trust, Bryan Cox and Sarah Cox for $31 million.	09/23/09	CI

Chart Avalon GloboCare Corp.

Duration

Period

More charts

Company Profile

Avalon GloboCare Corp. is a commercial-stage company engaged in developing and delivering transformative, precision diagnostics and clinical laboratory services. The Company offers diagnostic testing utilizing proprietary technology to deliver genetics-driven results. It operates through two segments: Real property rental and Lab Services MSO. Lab Services MSO segment is focused on delivering services related to toxicology and wellness testing and provides a portfolio of diagnostic tests including drug testing, toxicology, and a range of test services, from general bloodwork to anatomic pathology, and urine toxicology. Its capabilities include STAT blood testing, qualitative drug screening, genetic testing, urinary testing, and sexually transmitted disease testing. The Lab Services MSO segment is also focused on the commercialization of genetic-based proprietary testing. It is also exploring the commercialization and development of a versatile breathalyzer system, KetoAir breathalyzer.

Sector

Healthcare Facilities & Services

More about the company

Income Statement Evolution

More financial data

Sector Medical & Diagnostic Laboratories

	1st Jan change	Capi.
AVALON GLOBOCARE CORP.	-38.92%	3.28M
SONIC HEALTHCARE LIMITED	-20.95%	7.83B
RADNET, INC.	+67.01%	4.29B
DR. LAL PATHLABS LIMITED	-1.32%	2.58B
SYNLAB AG	-8.93%	2.48B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-38.69%	2.46B
NEOGENOMICS, INC.	-10.75%	1.84B
FLEURY S.A.	-19.84%	1.53B
DIAN DIAGNOSTICS GROUP CO.,LTD.	-40.24%	1.22B
METROPOLIS HEALTHCARE LIMITED	+16.56%	1.2B

Medical & Diagnostic Laboratories